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Objectives. This study sought to determine the safety of deferral
of percutaneous transluminal coronary angioplasty (PTCA) of
angiographically intermediate but functionally nonsignificant ste-
nosis, as assessed by coronary pressure measurement and myo-
cardial fractional flow reserve (FFRmyo).
Background. Decision making in patients with chest pain and
intermediate coronary stenosis remains difficult. In these cases it
is unclear whether the risk of an intervention and the potentially
subsequent restenosis outweigh the future risk of an event if the
lesion remains untreated. FFRmyo is a lesion-specific functional
index of epicardial stenosis severity that accurately distinguishes
stenoses associated with inducible ischemia.
Methods. Retrospective analysis and follow-up was performed
in 100 consecutive patients referred to our centers for PTCA of an
intermediate stenosis but in whom the planned intervention was
deferred on the basis of an FFRmyo >20.75.
Results. During a follow-up period of 18 6 13 months (mean 6
SD, range 3 to 42), two patients died of noncardiac causes. Ninety
patients remained free of any coronary events, and their average
Canadian Cardiovascular Society class decreased from 2.0 6 1.2
at baseline to 0.7 6 0.9 at follow-up (p < 0.0001). A coronary
event occurred in eight patients and was target-vessel related in
four.
Conclusions. In patients with chest pain referred for PTCA of
an intermediate stenosis, deferral of the intervention on the basis
of an FFRmyo >20.75 is safe and is associated with a much lower
clinical event rate than if the procedure had been performed as
initially planned in these patients.
(J Am Coll Cardiol 1998;31:841–7)
©1998 by the American College of Cardiology
Patients with chest pain, a coronary artery stenosis and easily
inducible ischemia have a higher risk for a coronary event than
patients with a similar angiographic degree of stenosis but
without inducible ischemia or only ischemia at high levels of
exercise. It is therefore justifiable to treat angiographically
moderate but functionally significant stenoses (1–3).
However, clinical decision making in patients with persis-
tent typical or atypical chest pain and angiographically inter-
mediate stenosis, but no objective proof of inducible ischemia,
remains challenging. In those patients, despite repeated nega-
tive or inconclusive noninvasive stress tests, the question of
whether their complaints are related to that specific stenosis
often remains.
Although intermediate stenosis poses a certain prognostic
risk for a coronary event, only few quantitative data on the
extent of this risk are available (4). Even less is known about
whether this risk can be reduced by an intervention that has an
inherent risk of initiating the deteriorating process of plaque
activation and restenosis (5,6). For that reason, reliable meth-
ods for evaluating the functional significance of intermediate
lesions in the catheterization laboratory would be helpful in
making the decision to perform dilation. If functionally signif-
icant (i.e., capable of inducing reversible ischemia), the respec-
tive stenosis could be dilated; if not, percutaneous transluminal
coronary angioplasty (PTCA) could be deferred.
As we recently showed (7), myocardial fractional flow
reserve (FFRmyo), calculated from coronary pressure measure-
ments, is a useful index for determining the functional severity
of an intermediate coronary stenosis. Several studies (8,9) have
convincingly demonstrated that an FFRmyo of 0.75 accurately
discriminates lesions capable of inducing reversible ischemia at
exercise from those not capable of doing so.
The aim of this study was to investigate retrospectively the
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safety and long-term outcome of deferring a coronary inter-
vention in patients initially referred for PTCA of an interme-
diate coronary stenosis, but in whom the intervention was
deferred on the basis of a sufficiently high FFRmyo $0.75.
Methods
FFRmyo. The FFRmyo of a coronary artery is defined as the
ratio between maximal achievable blood flow to its dependent
myocardium and the hypothetically maximal achievable blood
flow to that same territory if the supplying artery were com-
pletely normal (10). Contrary to absolute coronary flow re-
serve, FFRmyo is independent of changes in systemic blood
pressure and heart rate and is not affected by conditions known
to increase baseline myocardial blood flow (8,11). In addition,
FFRmyo takes into account collateral blood flow to the depen-
dent myocardium (12). FFRmyo can be easily and rapidly
obtained during cardiac catheterization as the ratio between
distal hyperemic coronary pressure, measured by a pressure
guide wire, and aortic pressure, measured by the guiding
catheter (8). The normal value of this index is 1.0 and because
there is no need for a control artery, it is also applicable in
multivessel disease (8).
Patients. Between May 1993 and May 1997 at our centers
in Aalst and Eindhoven, guide wire-based coronary pressure
measurements to determine FFRmyo were performed in .600
patients, either at diagnostic or at interventional catheteriza-
tion. From this patient group all records were reviewed to
select the first 100 patients who fulfilled the following inclusion
criteria: 1) Patients were referred for intervention of one
stenosis in the mid or proximal part of a native coronary artery;
2) the myocardial territory dependent on the stenosed target
vessel was normokinetic, as assessed by visual estimation of the
ventriculogram; and 3) the planned intervention was deferred
on the basis of a pressure-derived FFRmyo $0.75, determined
during the control angiogram just before the planned PTCA.
Coronary catheterization and coronary pressure measure-
ment. In all patients, at the time of the planned PTCA, a 6F to
8F guiding catheter was introduced into the femoral artery and
advanced into the ostium of the target vessel. Intracoronary or
sublingual nitroglycerin and 10,000 U of heparin were admin-
istered just before control angiograms were made, according to
local routine. Thereafter, a pressure monitoring guide wire
(Pressure Guide, Radi Medical Systems, Uppsala, Sweden)
was zeroed, calibrated and advanced through the catheter into
the coronary artery and positioned distal to the stenosis, as
previously described (8). Next, maximal myocardial hyperemia
was induced by adenosine, either as an intracoronary bolus of
12 to 20 mg or by intravenous infusion in a femoral vein at an
infusion rate of 140 mg/kg body weight per min for a duration
of 2 to 4 min (13–15). Examples of the angiogram and pressure
recordings from one study patient are shown in Figures 1 and
2, respectively.
FFRmyo was then calculated at maximal hyperemia from
the simultaneously recorded aortic (Pa) and distal coronary
pressure (Pd) by the ratio
FFRmyo 5 Pd/Pa,
as described previously (8).
Abbreviations and Acronyms
CCS 5 Canadian Cardiology Society
FFRmyo 5 myocardial fractional flow reserve
Pa 5 mean aortic pressure
Pd 5 mean distal coronary pressure, measured at
maximal coronary hyperemia
PTCA 5 percutaneous transluminal coronary angioplasty
QCA 5 quantitative coronary arteriography
Figure 1. Coronary angiogram in right anterior oblique projection
from a 77-year old woman with persistent chest pain and negative
noninvasive stress test results but admitted for PTCA of a 70% stenosis
in the proximal left anterior descending coronary artery (arrow). The
dilemma was to perform angioplasty or to leave this lesion untreated.
The pressure tracings from this patient are shown in Figure 2.
Figure 2. Simultaneous phasic and mean pressure recordings of distal
coronary pressure (Pd), and aortic pressure (Pa) in the patient from
Figure 1. The pressure wire is positioned across the stenosis, and no
gradient is observed at rest (RESTING). After start of intravenous
adenosine infusion (140 mg/kg per min), a pressure gradient gradually
develops, and at steady state maximal coronary hyperemia (HYPER-
EMIA), FFRmyo is calculated by the Pd/Pa ratio, which equals 82/93 5
0.89. This value is well above the cutoff point of 0.75 for reversible
ischemia; therefore, no intervention was performed.
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Quantitative coronary arteriography. Quantitative coro-
nary arteriographic (QCA) analysis of the control cine angio-
grams, obtained just before the planned intervention in pref-
erably two orthogonal projections by the cardiovascular
angiography analysis system (16,17), was performed. Using the
guiding catheter as a scaling device, the reference diameter,
minimal lumen diameter, percent diameter stenosis and per-
cent area stenosis of the target lesion were assessed. The values
presented are the average of the orthogonal projections.
Follow-up and clinical events. Follow-up clinical data were
obtained in all patients by patient interview and by written
correspondence with the cardiologist who was presently treat-
ing or had last treated the patient. Clinical events were
mutually exclusive and were defined in the following ranking
order as death, myocardial infarction, unstable angina, coro-
nary artery bypass graft surgery and coronary angioplasty.
Death was considered cardiac related, unless proved otherwise.
Coronary events were subclassified into target vessel related or
target vessel unrelated.
The decision not to perform the planned angioplasty re-
quired extensive explanation to the patient and the referring
cardiologist. In particular, it was explained that the decision to
defer the intervention was based on coronary pressure mea-
surements indicating adequate myocardial perfusion and that
the operator had concluded that the lesion could not be held
responsible for the patient’s chest pain. Decisions regarding
medical treatment of the patient after deferral of PTCA were
left to the referring physician.
Statistics. Data are reported as number of patients and
mean value 6 SD. Differences between mean CCS class and
mean number of antianginal drugs used at baseline and at
follow-up were determined using the Wilcoxon test. Differ-
ences between mean percent diameter stenosis and FFRmyo in
the event-free and event group were assessed using the t test.
A p value , 0.05 was considered significant, and all tests were
two-tailed. Patient curves for freedom from death and coro-
nary events were constructed according to the method of
Kaplan and Meier (18).
Results
Baseline characteristics. The clinical characteristics of the
study patients are shown in Table 1. At least one noninvasive
stress test had been performed in 64 patients, of whom 28 had
a positive result for ischemia. Therefore, in a total of 72
patients, noninvasive stress tests for ischemia were negative
(n 5 30), inconclusive (n 5 6) or not available (n 5 36). In
those patients, the decision to schedule PTCA had been based
solely on persistent chest pain and the presence of an angio-
graphically suspect lesion. Ten patients were in CCS class I but
were referred for an intervention on the basis of coincident
positive stress test results and the presence of an intermediate
stenosis.
Angiographic characteristics and FFRmyo. The lesion char-
acteristics, as well as the results of the pressure measurements,
are shown in Table 2. The target lesion was located in the
proximal or midsection of the left anterior descending coro-
nary artery in 64 patients, the left circumflex coronary artery in
10 and the right coronary artery in 26. Quantitative coronary
angiographic analysis of the reference diameter of the adjacent
normal segment, minimal stenosis lumen diameter, percent
diameter stenosis and percent area stenosis resulted in average
values of 3.17 6 0.67 mm, 1.68 6 0.45 mm, 46.9 6 9.4% and
68.5 6 10.5%, respectively (Table 2). In 40 patients, the
percent diameter stenosis was .50%. In 35 patients, the
minimal lumen diameter was ,1.5 mm. The average FFRmyo
was 0.87 6 0.07 (range 0.75 to 1.00). The average peak
hyperemic transstenotic pressure gradient was 12 6 6 mm Hg
(range 0 to 24).
Procedural safety and follow-up. There were no proce-
dural complications related to catheterization or coronary
pressure measurements. Complete clinical follow-up was ob-
tained in all patients. The average follow-up period was 18 6
Table 1. Baseline Clinical Characteristics of 100 Patients in Whom
Planned Percutaneous Transluminal Coronary Angioplasty Was
Deferred on the Basis of Coronary Pressure Measurements
Age (yr) 61 6 11
Range 33–83
Men 69
Baseline CCS class 1.9 6 1.2
Estimated LVEF (%) 66 6 12
Patients with
Diabetes mellitus 17
Hypertension 37
Smoking, ever and current 39
Hypercholesterolemia 37
Family Hx of CAD 43
Prev coronary events 41
Prev angioplasty of target vessel 22
Prev angioplasty of other vessel 9
Prev CABG other vessel(s) 5
Prev MI related to other vessel 6
Prev aborted MI related to target vessel 8
Atypical complaints 41
Typical complaints 59
One-vessel disease 64
Two-vessel disease 30
Three-vessel disease 6
Pre-PTCA stress test result available 64
Pre-PTCA stress test result
Positive 28
Negative 30
Inconclusive 6
Patients using
Aspirin 83
Beta-blockers 58
Ca antagonists 49
Nitrates 45
Antianginal drugs at baseline 2.4 6 1.2
Data presented are mean value 6 SD, range or number of patients. Ca 5
calcium; CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery
disease; CCS 5 Canadian Cardiovascular Society; Hx 5 history; LVEF 5 left
ventricular ejection fraction; MI 5 myocardial infarction; Prev 5 previous;
PTCA 5 percutaneous transluminal coronary angioplasty.
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13 months (range 3 to 42) and was .6 months in 79 patients.
During the follow-up period (Table 3), two patients died of
noncardiac causes after 3 and 10 months, respectively. The first
was a 49-year old man with atypical complaints and a mild
aortic stenosis (mean gradient 12 mm Hg), who committed
suicide 3 months after catheterization. The second was a
77-year old man who died of a gastric cancer. In this patient
with chest pain and known coronary disease, gastrectomy was
considered. Intracoronary pressure measurements were per-
formed to evaluate the need for preoperative PTCA of the
stenosis. PTCA was deferred on the basis of an FFRmyo of
0.89. No cardiac-related deaths occurred.
In eight patients coronary events occurred, four of which
were target vessel related (Table 3). The characteristics of
these patients are shown in Table 4. The average interval to a
target vessel-related incident was 27 months, whereas the
average interval to incidents not related to the target vessel was
11 months. Only two coronary events occurred within 6 months
after deferral, and both were unrelated to the target vessel.
There was no difference in QCA variables (p 5 0.909) or in
FFRmyo (p 5 0.374) at the initial assessment between patients
with an event at follow-up and the remaining group.
The average CCS class in the event-free group (90 patients)
decreased from 2.0 6 1.2 at baseline to 0.7 6 0.9 at follow-up
(p , 0.0001). The average number of antianginal drugs used in
these 90 patients decreased from 2.4 6 1.2 at baseline to 1.9 6
1.2 at follow-up (p 5 0.0022). At follow-up, 81 patients were in
CCS class I or had no chest pain.
Survival and event-free survival. As analyzed by the
Kaplan-Meier method, at 42 months the percent estimated
survival (6SEM) after deferral of PTCA was 97 6 2%; survival
free from death or target vessel-related events was 84 6 7%;
and survival free from death or any coronary event was 78 6
7% (Fig. 3).
Discussion
Favorable outcome without intervention. The present
study indicates that it is safe to defer angioplasty of an
intermediate stenosis if that stenosis has no physiologic impor-
tance, as assessed by pressure-derived FFRmyo $0.75.
No cardiac-related deaths occurred in our deferred group,
and during an average follow-up period of 18 months, a target
vessel-related event occurred only in 4 of 100 patients. Only
one patient experienced a myocardial infarction after 26
months because of disease progression in the target vessel. The
average reference diameter of the coronary arteries in the
present study was .3 mm, indicating that these were all large
vessels and that the favorable outcome was not due to inclusion
of smaller vessels that would have had a good outcome in any
case.
Rationale of coronary pressure measurement. FFRmyo is a
functional index of epicardial stenosis severity, and it has been
well demonstrated (7,8) that the cutoff value of 0.75 discrimi-
nates between functionally significant and nonsignificant ste-
noses. The diagnostic accuracy of FFRmyo for this purpose is
93% and is higher than any other single noninvasive stress test
if performed alone (7). Therefore, in our catheterization
laboratories, it is standard practice to determine the FFRmyo if
there is reasonable doubt that the culprit lesion scheduled for
PTCA is actually causing the complaints. Such is often the case
when the lesion is moderate and the exercise test not clearly
positive or when the complaints are atypical. FFRmyo is easily
obtained just before PTCA by using a pressure guide wire
instead of a regular guide wire and by measuring distal
coronary pressure and aortic pressure simultaneously at max-
imal hyperemia.
In patients with persistent chest pain, coronary angiography
is often performed despite the absence of objective proof of
ischemia (7,19). It has been shown (20) that in a randomly
selected group of asymptomatic 60-year old men, the preva-
Table 2. Angiographic Characteristics and Myocardial Fractional
Flow Reserve in 100 Study Patients
Coronary artery involved
LAD 64
LCx 10
RCA 26
QCA
Ref diam (mm) 3.17 6 0.67
MLD (mm) 1.68 6 0.45
%DS 46.9 6 9.4
% area stenosis 68.5 6 10.5
Patients with
%DS .50% 40
MLD ,1.5 mm 35
FFRmyo 0.87 6 0.07
Range 0.75–1.00
Peak hyperemic transstenotic pressure gradient (mm Hg) 12 6 6
Range 0–24
Data presented are mean value 6 SD, range or number of patients. DS 5
diameter stenosis; FFRmyo 5 myocardial fractional flow reserve; LAD 5 left
anterior descending coronary artery; LCx 5 left circumflex coronary artery;
MLD 5 minimal lumen diameter; QCA 5 quantitative coronary arteriography;
RCA 5 right coronary artery; Ref diam 5 reference diameter.
Table 3. Follow-Up and Clinical Events in 10 Study Patients
Average follow-up (mo) 18 6 13
Pts with clinical event at follow-up 10
Interval to clinical event (mo) 17 6 11
Range 3–32
Noncardiac death (n 5 2)
Suicide 1
Gastric cancer 1
Cardiac death 0
MI related to target vessel 1
MI related to other vessel 0
UA related to target vessel 2
UA related to other vessel 2
Elective CABG, including target vessel 1
Elective PTCA related to disease progression in target vessel 0
Elective PTCA related to disease progression in other vessel 2
Data presented are mean value 6 SD, range or number of patients. Pts 5
patients; UA 5 unstable angina; other abbreviations as in Table 1.
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lence of apparently significant coronary stenoses is 20%.
Therefore, one must assume that in a number of such patients,
the presence of a lesion may be coincidental and that a direct
relation between the angiographic lesion and the chest pain is
unclear. Nevertheless, in clinical practice, PTCA of the inter-
mediate lesion is often performed despite the absence of
objective proof of ischemia (19). This practice has been
defended in that even if that lesion is not related to the
patient’s chest pain, PTCA would be justified by the “plaque-
sealing” concept (21). However, this concept is unproved, and
in so performing PTCA, a previously stable (and functionally
not significant) lesion might be activated and a deleterious
“restenosis” process triggered. In fact, it is expected that in
20% to 30% of such patients, a clinically relevant restenosis
will occur within 6 months. It is therefore unclear whether the
risk of dilating a functionally nonsignificant but angiographi-
cally intermediate stenosis outweighs the risk of leaving such a
lesion untreated.
Evidence of reversible ischemia as a prerequisite for per-
forming PTCA. In the present study, 72 patients had been
scheduled for angioplasty only on the basis of clinical and
visual angiographic criteria. Stress testing in these patients
was either negative, inconclusive or not performed. Al-
though our study cohort was restricted to patients with in-
termediate stenoses, their data are comparable to those of a
general PTCA population, as reported by Topol et al. (19),
indicating that in the United States, .60% of coronary
interventions are performed without objective proof of
reversible ischemia.
By QCA, 40 of 100 stenoses in the present study group
appeared to be .50% in diameter stenosis, the anatomic cutoff
value generally accepted for discriminating between “signifi-
cant” and “nonsignificant” lesions. Such lesions would have
been routinely dilated had only angiographic criteria been
applied (22,23). However, by our measuring FFRmyo, a num-
ber of unnecessary PTCAs were avoided in this group.
Although the rate of clinical events in the present study is
markedly lower than that usually reported after angioplasty, it
may be argued that in recent angioplasty trials, lesions under-
going a coronary intervention, were on average more symp-
tomatic, had a larger degree of obstruction as assessed by
quantitative coronary angiography and were all associated with
positive exercise tests. Nevertheless, it is noteworthy that in
those studies a coronary event rate of ;30% was reported
within 12 months after balloon angioplasty alone and ;15%
after stenting (24). In the present study, no target vessel-
related events occurred within the first 6 months of follow-up,
Table 4. Coronary Events in Eight Study Patients
Pt No./
Gender Age (yr)
Target
Vessel
Initial
FFRmyo %DS
Interval to Event
(mo) Incident
Patients With Coronary Event Related to Target Vessel (n 5 4)
1/M 83 LAD 0.89 28% 21 UA, followed by PTCA
2/M 60 RCA 0.85 58% 26 Acute MI
3/M 61 RCA 0.94 61% 30 UA, followed by PTCA
4/M 67 RCA 0.85 40% 32 CABG, including target vessel
Mean 68 0.89 47% 27
6SD 64 60.04 616% 65
Patients With Coronary Event Not Related to Target Vessel (n 5 4)
5/M 66 RCA 0.94 49% 5 UA, followed by PTCA
6/M 51 LCx 0.85 52% 6 Disease progression, elective PTCA
7/F 69 LCx 0.91 48% 8 Disease progression, elective PTCA
8/F 59 LAD 0.94 42% 26 UA, followed by PTCA
Mean 61 0.90 48% 11
6SD 68 60.04 64% 610
F 5 female; M 5 male; Pt 5 patient; other abbreviations as in Tables 1 to 3.
Figure 3. Estimated survival and event-free survival curves (Kaplan-
Meier) of all patients in whom the planned PTCA of an intermediate
coronary stenosis was deferred on the basis of a pressure-derived
FFRmyo $0.75. Numbers below the x-axis represent patients at risk at
0, 6, 12, 18, 24, 30, 36 and 42 months after deferral of angioplasty for
survival; survival or target vessel-related event; and survival or any
coronary event, respectively.
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and only in 10% of this study group did events occur after an
average follow-up of 18 months. This event rate is only slightly
above the coronary event rate found in an asymptomatic
60-year old population of ;2% to 3%/year and is in accor-
dance with previous studies (7,25–27) in similar patient groups
where intervention was deferred on the basis of physiologic
measurements of either coronary blood flow velocity or coro-
nary pressure.
In 28 patients the pre-PTCA exercise test was positive
despite a FFRmyo .0.75. Exercise-induced spasm may have
played a role in some patients, and the exercise test could have
been false positive in others. It is well known that the accuracy
of exercise testing in patients with moderate stenosis is low and
that false positive results may occur in up to 20% of these
patients (7). Moreover, as described earlier, in 10 of these 28
patients no complaints were present, and the indication for
angiography, which revealed the intermediate stenosis, had
been the positive exercise test itself. In those patients the rate
of false positive exercise tests must have been higher than usual
(27). Two of these 28 patients experienced a coronary event,
respectively, at 20 and 24 months, both target vessel related.
This long event-free interval suggests that these events may
have been related to the natural progression of atherosclerotic
disease rather than to incorrect initial diagnosis.
In the 90 event-free patients, anginal class improved signif-
icantly at follow-up despite a decrease in the average number
of antianginal medications taken by these patients. This im-
provement is possibly related to patient reassurance by our
explaining that the lesion was not clinically important and that
the chest pain could very well be of other than cardiac origin
(7,25). This decrease in symptoms after reassurance supports
the idea that in many of these patients the chest pain was not
caused by the coronary lesion, underlining that deferral of the
planned PTCA had been the correct decision.
Indications for coronary pressure measurement before
PTCA. As stated earlier, in our catheterization laboratories
coronary pressure measurement and determination of FFRmyo
are routinely performed in patients in whom reasonable doubt
exists about the significance of coronary lesions, either at
diagnostic angiography or just before planned PTCA. This is
the case in ;10% of our patients and relates to intermediate
stenosis, equivocal noninvasive stress test results or atypical
complaints. Other indications are facilitating the decision to
perform either PTCA of one or two vessels or bypass surgery
of three or more vessels, depending on the significance of the
respective lesions, or to decide whether minimal invasive
surgery of a left anterior descending coronary artery stenosis is
a reasonable option for multivessel disease (28). The technique
of coronary pressure measurement is easily applicable during a
routine procedure, and additional costs are U.S.$500 for the
pressure wire in cases of PTCA and an additional U.S.$150 in
a diagnostic case for the Y-connector and a (generally 6F or
7F) guiding catheter. If FFRmyo .0.75, intervention of the
respective lesion is always deferred. Therefore, selection bias
was unlikely in the present study.
Conclusions. Because this study is retrospective and non-
randomized and does not provide comparative data from a
control group of patients in whom angioplasty was actually
performed, it is impossible to establish the clinical event rate
that would have occurred had angioplasty actually been per-
formed. Nevertheless, it can be concluded that in patients with
chest pain who are scheduled for PTCA of an intermediate
coronary stenosis, deferral of PTCA on the basis of an FFRmyo
.0.75 is safe, irrespective of the noninvasive stress test result,
and is associated with a very low coronary event rate of
;5%/year, much lower than expected had PTCA been per-
formed in all patients. To confirm these observations, a large
randomized, prospective study is currently underway.
We are grateful to the referring cardiologists of the study patients for their
contribution during follow-up and to Bert Jan Arends, BSc for expert statistical
assistance.
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